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ABSTRACT _
This paper highlights some of the problems associated
with lipid therapy in the primary and secondary preven-
tion of cardiovascular disorders and to make some poten-
tially useful suggestions in the context of managed care.
For managed care organizations, financial and logistical
issues create obstacles to the provision of primary preven-
tion of cardiovascular disease. These current obstacles
necessitate the generation of external forces, perhaps reg-
ulatory or standards agencies, that may help increase ac-
countability in managed care organizations for midterm
The delivery of lipid therapy faces many chal-lenges in the managed care setting. Based on
health data gathered from a large health mainte-
nance organization (HMO) and pharmacy benefit
manager (Integrated Pharmaceutical Services, Ran-
cho Cordova, CAl, guidelines for the provision of
lipid therapy have been established in conjunction
with the University of Arizona and Stuart Disease
Management Services using the National Cholesterol
Education Program (NCEP) standards [1]. These
guidelines include recommendations for exercise,
diet, lifestyle modification, education, and drug ther-
apy. Despite such guidelines, several logistical, medi-
cal, and economic obstacles impede the adequate
provision of lipid therapy in a managed care environ-
ment. The purpose of this paper is to highlight some
of the problems associated with lipid therapy in the
primary and secondary prevention of cardiovascular
disorders and to suggest some potentially useful solu-
tions in the context of managed care.
Lipid Therapy and Primary Prevention
The financial incentive for providing primary pre-
vention of lipid disorders is questionable. To illus-
trate this issue, we can project calculations using as
an example a hypothetical HMO with 2.5 million
members having a membership with normal age
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and distant outcomes. In contrast, the provision of sec-
ondary prevention by managed care organizations has
fewer limitations. One of the major challenges in second-
ary prevention, however, is the low rate of physician
compliance with national treatment guidelines and stan-
dards. Among possible explanations for this observation
are limitations in health data collection and integration.
Improvements in data management are vital to the
achievement of treatment goal optimization in secondary
prevention.
distribution, male to female ratio, and incidence of
lipid abnormalities. Considering an average HMO
premium, the proportion of members requiring
therapy based on standard guidelines, and the aver-
age cost of therapy, the provision of primary pre-
vention in this hypothetical HMO would entail an
approximate net loss of $60 million per year. Fur-
thermore, assuming an average member age of 40
years, average time to a first cardiac event would be
greater than 5 years. Since the average duration of
HMO membership is less than 2 years, failure to
provide primary prevention is not likely to have
any negative financial consequences for the HMO.
Despite the recommendations for measurement of
cholesterol levels by the National Committee for
Quality Assurance (NCQA) and its Health Plan
Employer Data and Information Set (HEDIS) [2],
there is no incentive for managed care providers to
deliver primary preventive care for lipid disorders.
Another obstacle to primary prevention is the vari-
ability of benefit structures across different man-
aged care plans. Plans may limit the coverage of nu-
tritional services, behavior modification, education,
and drug benefits. Furthermore, a misalignment of
financial incentives to pharmacy benefit, physician
coverage, and hospital expenditure are actually
likely to lower priority for primary prevention.
To reconcile the importance of preventive ther-
apy with the issues of financial disincentive, it ap-
pears to be necessary to develop external pressures
that will effectively persuade managed care organi-
zations to provide primary prevention. While this
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might involve regulatory intervention, perhaps the
development of standards by external agencies such
as the Foundation for Accountability might serve to
increase accountability of HMOs for distant out-
comes [3].
Lipid Therapy and Secondary Prevention
The provision of secondary prevention by managed
care providers is considerably less limited than for
primary prevention, but problems do exist. Modifi-
cations of the data management process may help
to improve this effort. Happily, there is more con-
sistent adherence to the spirit of national guidelines
and standards in secondary prevention. Members
of an HMO already diagnosed with specific diseases
are easily identified, and their treatment (unlike the
prevention of possible future diseases) leads to a
more quantifiable outcome. Thus, secondary pre-
vention is more marketable and, subsequently, fi-
nancial payback more proximal. A major challenge
in the provision of secondary prevention is the ex-
tremely low rate of physician compliance with na-
tional treatment guidelines and standards. Our own
data indicate that compliance of treatment to goal is
approximately 5%, whether physicians are capped
or fee-for-service, suggesting that incentive does not
play a major role here (internal data, Integrated
Pharmaceutical Services, Rancho Cordova, CA). The
biggest obstacle to compliance with secondary pre-
vention guidelines and standards appears to be lim-
ited data management. Limitations in the provision
of patient information from managed care organiza-
tions to physicians and vice versa are further com-
pounded by the difficulty of integrating informa-
tion from large datasets, such as laboratory values,
patient-chart data, and pharmacy claims. Despite
claims to the contrary, most managed care organi-
zations do not have adequate data integration sys-
tems. Delegation of data management to external
information management firms that have this capa-
bility may help close the feedback loop and boost
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compliance rates to more acceptable levels. At a
staff model medical group with which I was associ-
ated, we were able to improve compliance in pre-
scribing habits of physicians by providing informa-
tion feedback alone (not using financial incentives
or disincentives).
Conclusions
We face many challenges to the provision of pri-
mary and secondary preventive care to established
national standards in the managed care setting.
Changes that may promote closer achievement of
these goals include 1) properly aligned incentives
for physicians, and 2) the generation of external de-
mands that will effectively motivate managed care
organizations to take appropriate action. Finally,
more comprehensive data management and inte-
gration, as well as closing the information feedback
loop with physicians, is vital to achieve lipid treat-
ment goal optimization. External pressure or regu-
lation may be necessary to level the playing field, so
as not to provide a disincentive for those plans at-
tempting to provide appropriate lipid therapy and
other preventive services.
This article was preparedwith the assistance of BioMed-
Com Consultants inc.,Montreal, Canada.
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